Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Stavudine versus zidovudine and the development of lipodystrophy
Autore:
Bogner, JR; Vielhauer, V; Beckmann, RA; Michl, G; Wille, L; Salzberger, B; Goebel, FD;
Indirizzi:
Univ Hosp Munich, Med Poliklin, Dept Infect Dis, Munich, Germany Univ HospMunich Munich Germany iklin, Dept Infect Dis, Munich, Germany Univ Bielefeld, Fak Gesundheitswissensch, D-4800 Bielefeld, Germany Univ Bielefeld Bielefeld Germany D-4800 ensch, D-4800 Bielefeld, Germany Univ Cologne, Med Klin 1, AG Infektiol, Cologne, Germany Univ Cologne Cologne Germany Med Klin 1, AG Infektiol, Cologne, Germany
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 3, volume: 27, anno: 2001,
pagine: 237 - 244
SICI:
1525-4135(20010701)27:3<237:SVZATD>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
REVERSE-TRANSCRIPTASE INHIBITORS; ANTIRETROVIRAL THERAPY HAART; PROTEASE INHIBITORS; INSULIN-RESISTANCE; HIV-INFECTION; METABOLIC ABNORMALITIES; FAT DISTRIBUTION; HYPERLIPIDEMIA; PATHOGENESIS; WOMEN;
Keywords:
cholesterol; HIV; lipodystrophy; stavudine; zidovudine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Bogner, JR Univ Munich, Med Poliklin, Dept Infect Dis, Pettenkoferstr 8A, D-80336 Munich, Germany Univ Munich Pettenkoferstr 8A Munich Germany D-80336 , Germany
Citazione:
J.R. Bogner et al., "Stavudine versus zidovudine and the development of lipodystrophy", J ACQ IMM D, 27(3), 2001, pp. 237-244

Abstract

The pathogenesis of some components of the lipodystrophy (LD) syn drome might be linked to the use of nucleosides. Earlier reports did not compare treatment regimens according to the nucleoside backbone. We studied a cohort of individuals who did not switch between stavudine and zidovudine. LD was defined to be present if one of three criteria was met: self-report by the patient, observation by an investigator who had known the patient since commencement of highly active antiretroviral therapy (HAART), or examination by a physician masked to therapy. The mean duration of therapy was 101 weeks(range: 26-234 weeks). Overall prevalence of LD was 48.7%. Lipoatrophy andlipohypertrophy occurred in 33.9% and 28.7% of patients, respectively. Logistic regression showed four parameters to be significantly associated withlipoatrophy: HAART longer than 2 years (p = .002, odds ratio [ORI = 4.4, 95% confidence interval [CI]: 1.608-11.965), baseline viral load > 100,000 copies/ml (p = .004, OR = 4.3, CI: 1.726-11.197), age > 40 years (p = .016, OR = 3.2, CI: 1.247-8.373), and white ethnicity (p = .041, OR = 5.4, CI: 1.070-28.184). Cholesterol levels of > 200 mg/dl at baseline were associated with a risk reduction (p = .047, OR = 0.36, CI: 0.130-0.987). Use of lipohypertrophy as a dependent variable resulted in a significant association with HAART duration (p = 0.028, OR = 2.7, CI: 1.2-6.5) and protease inhibitor use (p = .014, OR = 3.8, CI: 1.3-11.2). LD prevalence is similar with both backbones using stavudine or zidovudine. This is the first time that baseline cholesterol uas shown to be significantly associated with lipoatrophy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 06:56:11